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Evidence for allosteric variants of wild-type p53, a tumour suppressor
protein
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Summary A tumour suppressor function for p53 is indicated in human lung cancer and in carcinoma of the
colorectum. Loss of suppressor function, by mutation of the p53 gene, is associated with activation of p53 as
an oncogene. The suppressor (wild type) and oncogenic (mutant) forms of the murine p53 protein are
distinguishable at the molecular level by reactivity with anti-p53 monoclonal antibodies. For example,
activated mutant p53 fails to react with PAb246 (p53-246°). We now demonstrate that wild type p53 mRNA
can be expressed either as pS3-246+ or p53-246°. We propose that p53-2460 may represent an allosteric variant
of wild type p53 compatible with positive growth control. Thus, for wild type p53 the variants p53-246+ and
p53-2460 may reflect suppressor and activator functions of p53 in the normal control of cell proliferation. For
human p53 we present evidence that the epitope recognised by PAb1620 is analogous to that for PAb246 on
murine p53. Thus the epitope for PAbl620 may prove to be of use as a marker for wild type human p53 with
anti-oncogenic function.
The p53 gene is highly conserved (Soussi et al., 1987) and is
regulatory for cell proliferation (Milner & Milner, 1981;
Mercer et al., 1982; Reich & Levine, 1984). In human colo-
rectal carcinoma a tumour suppressor function for p53 is
indicated, since progression to pre-malignant and malignant
phases correlates with loss of wild type p53 (Baker et al.,
1989). Allelic degeneration of p53 is also strongly implicated
in human carcinoma of the lung (Takahashi et al., 1989).
Mutation within the p53 gene can result in oncogenic activa-
tion and the mutant p53 can co-operate with ras in cell
transformation (Hinds et al., 1989; Eliyahu et al., 1988).
Experimental studies on p53 function have mainly involved
the murine p53 protein for which monoclonal antibodies
reactive with several discrete epitopes are available (see
Yewdell et al., 1986). Different transformed cell lines express
immunological variants of p53, a given variant being charac-
teristic for a given cell line (Milner & Cook, 1986). In these
studies it was noted that the monoclonal antibody PAb246
failed to react with p53 from spontaneously transformed and
chemically transformed cells (Milner & Cook, 1986). Subse-
quent studies have revealed that the epitope for PAb246 is
lacking on activated mutants of the p53 protein (Hinds et al.,
1989).
We now present evidence that wild type p53 can adopt a
conformation apparently identical to the mutant p53-246°
protein. This discovery arose from studies on p53 expressed
in vitro, using wild type p53 cDNA. The observation that
wild type p53 protein can exist in two specfic configurations,
pS3-246+ and p53-246°, raises the possibility that p53 may
function as an allosteric protein in cell growth control. Using
the monoclonal antibody PAb1620 (Milner et al., 1987) we
also show that human p53 can exist in two specific
configurations, analogous to p53-246+ and p53-246° of the
murine p53 protein.
Materials and methods
Transcription and translation ofp53 cDNA
An expression plasmid containing full length murine p53
cDNA, designated pSP65m53 (Jenkins et al., 1984) was
transfected into E. coli, amplified and purified as detailed
in Gamble and Milner (1988). The plasmid was linearised
with HindIll and aliquots containing 1.0fig cDNA il-' in
double distilled water were stored at -20'C. The cDNA
was transcribed using SP6 RNA polymerase and the purified
p53 mRNA was stored as aliquots at -70'C. A second
plasmid, encoding human p53, was also used. This plasmid,
pSP65pS3H8, was constructed by V. Rotter using the human
p53 cDNA clone H8 (Harris et al., 1986). Transcription and
translation were as for the murine p53 cDNA.
For translation in vitro L35S methionine (40.5 TBq mmol-',
555 MBq ml-', Amersham International plc) was added to
mRNA dependent rabbit reticulocyte lysate to give a concen-
tration of 5% v/v. To this was added 1/10 volume of p53
mRNA. Translations were carried out at 30°C, typically for
1 h, and stopped by chilling on ice.
Several batches of reticulocyte lysate were used. Each had
been prepared according to the method of Pelham and Jack-
son (1976) and they were obtained from Dr Tim Hunt,
Department of Biochemistry, Cambridge University. Work-
ing stocks of supplemented reticulocyte lysate (Hunt & Jack-
son, 1974) were stored as aliquots at -70°C. The different
batches of reticulocyte lysate had been prepared at different
times, but otherwise were essentially identical (Tim Hunt,
personal communication).
Immunoprecipitations
For immunoprecipitation of p53 protein the reticulocyte
lysate was diluted I in 100 with lysis buffer (10 mM Tris base;
0.14 M NaCl and 0.5% NP40 adjusted to pH 8.0) and 100 il
aliquots were immunoprecipitated for I h on ice. Immune
complexes were absorbed with 10tlI of 10% formalin-fixed
Staphylococcus aureus (Kessler, 1975), washed and eluted by
boiling for 10 min in 50pl of sample buffer (Laemlli, 1970).
The following anti-p53 monoclonal antibodies were used:
PAb421 (Harlow et al., 1981); PAbl22 (Gurney et al., 1980),
RA3.2C2 (Coffman & Weissman, 1981; Rotter et al., 1980);
PAb242, PAb246 and PAb248 (Yewdell et al., 1986);
PAb200.47 (De Leo et al., 1979); PAbl620 (Milner et al.,
1987) and PAb6O7 (Gooding, unpublished).
Phosphorylation studies
The phosphorylation of p53 translated in reticulocyte lysate
was studied using gamma 32P-ATP (222 TBq, 370 MB2 ml-';
Amersham International plc). Translation mixtures were
prepared with either 35S-methionine or an equal volume of
unlabelled methionine (1 mM) and to these were added either
gamma 32P-ATP or water (1 in 2 vol/vol). The effect of
adding 32P-ATP at different times and for different periods
was checked. For immunoprecipitation the reticulocyte lysate
mix was diluted 1 in 20 with lysis buffer pH 8.0.
Electrophoresis and autoradiography
Proteins were resolved by SDS-polyacrylamide gel electro-
phoresis (PAGE) using 15% acrylamide with a 5% stacking
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gel. The gels were run for 3 h at 200 V, or overnight at 55 V. In the above experiments the batches of reticulocyte lysate Proteins were fixed (45% methanol, 7% acetic acid in water) represented pooled lysates from several rabbits. We next for 30 min, treated with Amplify for 15 min and radio- compared the translation of p53 by lysates prepared from labelled proteins were visualised by autoradiography. individual rabbits. These lysates were kindly made available by Tony Hunter (The Salk Institute, San Diego, CA, USA).
Complete lysates from seven rabbits were tested. Of these
Results seven lysates, five translated p53 mRNA into p53-246+ and two yielded p53-2460 (Table II). The individual rabbit lysates
Variant forms of wild type p53 expressed in vitro were classified into group 1, equivalent to batch type A; and
group 2, equivalent to batch type B. An additional antibody, Several batches of reticulocyte lysate were available for the PAb240, was kindly made available by David Lane specific- translation of the p53 mRNA. As a preliminary control the ally for use in these translation experiments. Interestingly the batches were compared, translating equal aliquots of a com- epitope recognised by PAb240 was detectable on p53-246° mon stock of murine p53 mRNA. Unexpectedly individual but not on p53-246+ (Table II). batches of lysate yielded either p53-246+ or p53-2460: these The immunoreactivity ofhuman p53 translated in vitro was batches of lysate were designated type A and type B respec- next investigated. The monoclonal antibody PAb246 is tively. A more detailed study revealed that the two variants species specific and fails to react with human p53 (Yewdell et of wild type p53 translated in vitro were immunlogically al., 1986). However, we have previously identified a mono- identical to wild type p53-246 + and mutant p53-2460 ex- clonal antibody, PAb1620, which crossblocks PAb246 on pressed in vivo (Figure 1 and Table I). murine p53 and which also recognises human p53 (Milner et The epitope recognised by PAb246 is conformation- al., 1987). Moreover the epitope recognised by PAbl620 is dependent and is destroyed by denaturation of the p53 conformation-dependent (as is the PAb246 epitope) and polypeptide. The observation that wild type p53 could be murine p53-2460 is consistently negative for the PAbl620 either positive or negative for the PAb246 epitope indicates epitope (Milner et al., 1987; see for example, Table II). Thus two alternative conformations of the p53 polypeptide. The we predict that the epitope for PAbl620 on human p53 may particular conformation adopted appeared to depend upon correlate with wild type p53 suppressor function in a manner some property intrinsic to the reticulocyte lysate used for similar to the PAb246 epitope on murine p53. It was translation of the p53 protein. Out of seven batches of therefore of interest to determine the immunoreactivity of reticulocyte lysate five were of type A (p53-246+) and two of human p53 translated by the various rabbit reticulocyte type B (p53-2460). The reproducibility of the results obtained lysates. Human p53 translated by lysates type A and group 1 with lysates type A and type B was tested in an extended was reactive with PAbl620 (Table II; Figure 2a). With series of some twenty experiments. The immunoreactivity of lysates type B and group 2 the translated human p53 was the translated p53 protein was invariant and dependent upon negative for the PAbl620 epitope (Table II, Figure 2b). lysate type, A or B. Reactivity with the monoclonal antibody PAb240 was similar
to that observed for murine p53 in that murine p53-2460 and
human p53-16200 were positive for PAb240 and vice versa
a 1 2 3 4 5 6 7 8 (Table II, Figure 2). Thus reactivity with PAb246/PAbl620
.. ...and PAb24O appears to be reciprocal on the native p53
Till. ME ~ ~ ~ p otein.
We next compared the translation properties of reticulo-
cytes lysate types A and B using murine p53 mRNA.
Kinetics ofp53 mRNA translation
b 1 2 3 4 5 6 7 8 The rate of p53 translation into 35S-labelled p53 was deter- mined both by pulse-labelling and by continuous labelling
... . ~~~~with 355-labelled methionine. Both methods gave essentially
g ~~~~~--5 ~~~~~the same results; those for continuous labelling are shown in
Figure 3. Maximal rates of "S-methionine incorporation into
p53 occurred within the first 30 min of translation and lysates
type A and type B gave remarkably similar results (Figure 3). The rate of appearance of conformation-dependent
epitopes on the translated p53 protein was also investigated, Figure 1 Immunoprecipitations of "5S-methionine labelled p53 taking aliquots of the translation mix at 10 min intervals for protein translated by mRNA dependent rabbit reticulocyte lysate up to 90mm. With lysate type A the p53 was reactive with as detailed in the text. Autoradiographs of p53 following PAb246 from 10mm onwards; with lysate type B the SDS-PAGE: tracks 1-8 are of p53 immunoprecipitated with the PAb246 from wa rds; at ll t ype B she following monoclonal antibodies: I = PAb421, 2=PAbl22, 3 = PAb246 epitope was undetectable at all times (not shown). PA32C2; 4= PAb248; 5 = PAb.200.47; 6= PAb246; 7=PAb607; These results indicated that with lysate type B the p53 pro- 8= PAb242. a = p53 from lysate type A; b =p53 from lysate type tein did not pass through a PAb246-positive form during the B. Exposure of autoradiographs: a = 24h; b = 18 h. period of translation.
Table I Immunological reactivity ofp53 translated in vitro and in vivo
Monoclonal antibodv
PAb421J PAbJ22a PAb248a RA32C2a PAb246b PAb6O7b PAbl620b PAb2oO.47- PAb242b BS
A + + + + + + + + + o SV3T3 + + + + + + + + + o B + + + + o o o + + o 3T12 + + + + o o o + + o
4 nimA U. 4fL--mncoa nioies- diece agis deauain-tbeeitps()ad eauaio estv aana D: antn-p3_i monoclonal anti-bodies directed against denaturation-stable epitopes (a) and denaturationlsensitive epitopes (b). n.b. These monoclonal antibodies recognise seven distinct domains on the p53 protein. Aand B:p53 translated inreticulocytelysatetypesAandB; SV3T3and 3T12 =p53 from SV3T3 and 3T12celllysates. SV3T3 and 3T12 cells express wild type and mutant p53 respectively.550 A. COOK & J. MILNER
Table II Immunological reactivity ofmurine and humanp53 translated in vitro using reticulocytelysates
prepared from individual rabbits
PAb421 PAb248 RA3 2C2 PAb246 PAb1620 PAb240 PAb242 BS
Group 1
Murine p53 + + + + + o + o
Human p53 + NR NR NR + o NR o
Group 2
Murine p53 + + + o o + + o
Human p53 + NR NR NR o + NR o
NR = not reactive due to species specificity of the monoclonal antibody (Yewdell et al., 1986).
a
b
1 2 3
1 2 3
Figure 2 Immunoreactivity of human p53 translated by reticulo-
cyte lysates prepared from individual rabbits. Examples of group
I and group 2 lysates are shown, panels a and b respectively.
Immunoprecipitations with PAb421 (lane 1), PAbl620 (lane 2)
and PAb240 (lane 3). Exposure of autoradiographs: 24 h for
panel a and 16 h for panel b.
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Lysate mixing experiments
The effect of lysate type B on p53-246+, and of type A on
p53-246°, was tested by mixing and incubating the translated
p53 protein with the appropriate lysate. The mixtures were
incubated in the presence of anisomycin to block further
protein synthesis. The effects of time, temperature and lysate
ratios were all tested. Both p53-246+ and p53-2460 were
stable in terms of their immunology and were not inter-
convertible by mixing respectively with lysates types B and A
under any of the conditions tested (not shown).
Having demonstrated the stability of p53-246+ and p53-
2460, once translated, we next tested the effect of translating
p53 mRNA in mixtures of lysate type A plus type B. The
results (Figure 4) indicated that lysate type B was dominant
since, in the presence of 20% lysate type B, the level of
p53-246+ was reduced by 50%. In the presence of 50%
lysate type B the p53 mRNA was translated into p53-2460.
Overall, these results indicate that the presence/absence of
the PAb246 epitope on wild type p53 is determined during
the translation of the p53 polypeptide. This co-translational
effect appears to be dependent upon factor(s) in lysate type B
that suppresses the p53-246+ conformation of p53.
Phosphorylation ofp53 translated in vitro
The p53 protein in vivo may be phosphorylated at several
sites, including serines 37, 312 and 389 (Samad et al., 1986;
Meek & Eckhart, 1987). Since the addition of one or more
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Figure 3 Kinetics of translation of p53 mRNA by reticulocyte
lysates types A and B. Incorporation of 35S-methionine into
TCA-precipitable counts at varying times of continuous labelling.
Similar kinetics were obtained with pulse labelling over the same
period. n.b. the incorporation of 35S-label into full length p53
protein was greater 95% TCA precipitable counts. X-X lysate
type A; O-O lysate type B.
% mixture
Figure 4 The immunology of p53 translated by mixtures of
reticulocyte lysates type A and type B. Varying proportions of
lysate types A and B were pre-mixed as indicated and p53
mRNA (I fil per 10 I mixed lysate) was added and translated in
the presence of 35S-methionine at 30°C for I h. The translated
product was immunoprecipitated and run out on SDS-PAGE
(Materials and methods) and the amounts of "5S-labelled p53
immunoprecipitated with PAb246 relative to PAb421 were quan-
titated by scintillation counting (I ttl aliquots of
immunoprecipitated p53) and by densitometry scanning of the
autoradiographed gel. Dotted line indicates the level of back-
ground with B5, a negative control immunoprecipitation.
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charged phosphate groups might affect the conformation of
the p53 polypeptide we next tested the ability of reticulocyte
lysate to phosphorylate p53 translated in vitro. The protein
kinase activity of reticulocytes includes a component that is
dependent upon cyclic AMP (cAMP) and accordingly the
phosphorylation studies were carried out in the presence and
absence of cAMP. Controls showed no effect of cAMP upon
the conformation of p53 translated in vitro. The endogenous
protein kinase activity of the reticulocyte lysate was high and
multiple 32P-labelled proteins were detected after incubation
with gamma 32P-ATP (not shown). Following immunoprecip-
itation with anti-p53 monoclonal antibodies, 32P-labelled p53
was clearly detectable (Figure 5a). Lysates type A and type B
both phosphorylated p53 in vitro.
The wild type p53 variants were indistinguishable by two-
dimensional gel electrophoresis (Figure Sb) and by peptide
mapping (not shown), consistent with p53-246+ and p53-246°
representing conformational variants of the full length p53
polypeptide. Full length p53 is also indicated by reactivity
with monoclonal antibodies directed against epitopes that
span the wild type p53 polypeptide (Table I and Figure 1).
Discussion
The functioning of p53 involves molecular interaction with
specific target proteins. The first cellular target to be
identified for wild type p53 is p34cdc2, a cell cycle control
protein (Milner et al., submitted).
The interaction between p53 and its target molecules will
be determined in part by the conformation of the p53
polypeptide. For example p53-246+ has a high affinity for
the large T antigen of simian virus 40 (SV40), whereas
mutant p53-2460 fails to bind SV40 large T (Sturzbecher et
al., 1987). The wild type variant p53-246° also fails to bind
SV40 large T (Milner & Cook, in preparation). Thus the
presence/absence of the PAb246 epitope signifies two
different functional states of the p53 protein. There is now
good evidence that p53-246+ (wild type) functions as a sup-
pressor for cell proliferation, while p53-2460 (mutant) has
oncogenic properties (Hinds et al., 1989; Baker et al., 1989;
Takahashi et al., 1989).
We now demonstrate that wild type murine p53 can be
expressed in the form p53-2460. This observation was com-
pletely unexpected since, hitherto, p53-246° was believed to
represent mutant p53. The results presented in this paper are
for wild type p53 expressed in vitro: the same stock of p53
mRNA being translated into p53-246+ by lysate A and into
p53-2460 by lysate B (Figure 1, Table I). These results
indicate that wild type p53 can exist in two specific tertiary
conformations. This raises the possibility that wild type p53
is subject to allosteric control. Given the dominant function
of wild type p53 as a suppressor for cell proliferation it is
conceivable that the normal cellular response to growth
stimulation will require transient inactivation of this p53
suppressor function. One mechanism could involve an allo-
steric change in p53, that is p53-246 + to p53-246°. This
would inactivate, for a transient period, p53 suppressor func-
tion and allow the cellular growth response. Indeed we now
have good evidence that growth stimulation induces a con-
formational effect on wild type p53 in vivo, detected by loss
of the PAb246 epitope (Milner & Watson, submitted).
Mutant p53-2460 is associated with loss of p53 suppressor
function. We now present evidence that wild type p53 can
also adopt the p53-2460 conformation. We propose that the
two conformational states of wild type p53 may represent
allosteric forms ofp53, with negative (p53-246+) and positive
(p53-246°) functions in cell growth control. Mutation within
the p53 gene may perturb tertiary folding of the p53 polypep-
a 1 2 3 4
_~~ ~ .
b
Figure 5 a, Immunoprecipitations of p53 translated in vitro in
the presence of gamma 32P-ATP for I h at 30°C.
Immunoprecipitations as follows: lane 1, PAb42I1; lane 2,
RA3.2C2; lane 3, PAb246; lane 4, B5, a negative control. The
results shown are for p53 mRNA translated with reitculocyte
Iysate type A. The position of pS3 (arrowed) was determined
using 35S-labelled pS3 as marker (not shown). b, Two-dimensional
gel electrophoresis of p53-246+ and p53-2460 translated in vitro.
Reticulocyte lysate types A and B were used to translate p53
mRNA. The immunology of p53-246+ (lysate type A) and p53-
2460 (lysate B) was confirmed by immunoprecipitations with
PAb241 and PAb246 (not shown). Aliquots of the undiluted
translation mix were subjected to two dimensional electrophoresis
and autoradiography. Panel 1, 2fil lysate type A (p52-246+);
panel 2, 2fLI lysate type B (p53-2460); panel 3, 1 tllIysate type A
plus I IL lysate type B.
tide in such a way as to destabilise p53 conformation
associated with negative growth control.
The availability of the monoclonal antibody PAbl620
allowed us to extend the above observations to human p53.
PAb246 is species specific and does not recognise human p53.
However, PAbl620 reacts with both murine and human p53
(Milner et al., 1987). The PAbl620 and PAb246 epitopes are
topologically related on murine p53 and they appear to be
coupled in terms of their presence/absence on protein (Milner
et al., 1987, see Tables I and II). By extrapolation we predict
that, for human p53, the PAbl620 epitope indicates wild type
suppressor function. Moreover, activating mutations within
the human p53 gene may yield p53-16200, analogous to
p53-246° for activated mutants of the murine gene. Thus the
epitope for PAbl620 has potential as marker for the wild
type p53 anti-oncogene.
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